The U.K. National Institute for Health and Care Excellence has issued a final appraisal determination recommending Novartis’ brolucizumab treatment for wet age-related macular degeneration.
The novel Beovu “could help minimize treatment burden, with more than 50% of patients maintained on 12-weekly dosing intervals immediately after the loading phase to week 48,” the company said in a press release.
The recommendation was based on the results of the phase 3 HAWK and HARRIER trials, in which brolucizumab showed noninferior improvement in best corrected visual acuity when
Uncategorized